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Abstract
Diamond Blackfan anemia (DBA), a syndrome primarily characterized by anemia and physical
abnormalities, is one among a group of related inherited bone marrow failure syndromes (IBMFS)
which share overlapping clinical features. Heterozygous mutations or single-copy deletions have

Address Correspondence to: Jason E. Farrar MD, 1 Children’s Way, MS 512-10, Little Rock, AR, 72202; Phone: 501-364-1494; Fax:
501-364-3634; jefarrar@uams.edu. Steven R. Ellis PhD, 319 Abraham Flexner Way, HSC Campus, Building A, Room 507,
Louisville, KY, 40202; Phone: 502-852-5222; srellis@louisville.edu.
Author Contributions
JEF, PQ, RF, KAO, ID, UR, AV, JML, DMB, and SRE conceived and designed the study. JEF, PQ, RF, AA, EA, ID, UR, AV, and
JML obtained essential clinical specimens and data for study. JEF, PQ, AA, ALH, SPr, SB and EG prepared specimens for the
Northern analysis and Bioanalyzer studies. ALH and SRE performed the Northern analyses. JEF, PQ, SPr, SB, EG, and SRE
performed the Bioanalyzer analyses. JEF, SPa, and ID analyzed sequence data. KAO and NES developed knockdown constructs and
performed the K562 and CD34 experiments. JEF, PQ, KAO, AA, EG, RJA, ID, UR, AV, JML, DMB and SRE analyzed the data. JEF
and SRE drafted the manuscript. All authors edited and approved the final version of the manuscript.

Farrar et al.

Page 2

NIH-PA Author Manuscript

been identified in 12 ribosomal protein genes in approximately 60% of DBA cases, with the
genetic etiology unexplained in most remaining patients. Unlike many IBMFS, for which
functional screening assays complement clinical and genetic findings, suspected DBA in the
absence of typical alterations of the known genes must frequently be diagnosed after exclusion of
other IBMFS. We report here a novel deletion in a child that presented such a diagnostic challenge
and prompted development of a novel functional assay that can assist in the diagnosis of a
significant fraction of patients with DBA.
The ribosomal proteins affected in DBA are required for pre-rRNA processing, a process which
can be interrogated to monitor steps in the maturation of 40S and 60S ribosomal subunits. In
contrast to prior methods used to assess pre-rRNA processing, the assay reported here, based on
capillary electrophoresis measurement of the maturation of rRNA in pre-60S ribosomal subunits,
would be readily amenable to use in diagnostic laboratories. In addition to utility as a diagnostic
tool, we applied this technique to gene discovery in DBA, resulting in the identification of RPL31
as a novel DBA gene.
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Introduction
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Diamond Blackfan anemia (DBA) is a bone marrow failure syndrome that usually manifests
as a macrocytic anemia in the first year of life [1]. In addition to anemia, approximately 50%
of patients with DBA may have a heterogeneous array of congenital anomalies including
thumb, craniofacial, cardiac, and urogenital abnormalities [2]. Mutations or single copy
deletions in twelve genes that encode proteins of the 40S (RPS7, RPS10, RPS17, RPS19,
RPS24, RPS26 and RPS29) or 60S (RPL5, RPL11, RPL15, RPL26 and RPL35A) ribosomal
subunits have been identified in patients with DBA [OMIM #612563, 613308, 612527,
105650, 610629, 613309, 603633, 612561, 612562, 615550, 614900, and 612528,
respectively] [3-14]. Many cases of DBA arise spontaneously as a result of a disruptive
alteration in one of two copies of a ribosomal protein gene; in familial cases, transmission is
typically autosomal dominant, indicating DBA is caused by haploinsufficiency for
ribosomal proteins. Mutations of a non-ribosomal protein, the erythroid transcription factor
GATA1 [OMIM# 300835], have also been identified in patients with DBA [15, 16]. Despite
significant progress in DBA gene discovery, the underlying genetic defect remains unknown
in 35-40% of patients.
Of the DBA patients whose genetic defect is unknown, it seems likely that some fraction of
the affected genes may also target ribosome synthesis whereas others may not. In principle,
it should be possible to functionally categorize those with ribosomal defects even when the
gene is unknown or if the nature of a putative gene variant is ambiguous. Pre-rRNA
processing has been used to define the effects of ribosomal protein deficiencies on ribosome
synthesis [17]. Suboptimal levels of a ribosomal protein interfere with ribosome assembly,
which can be assayed by tracking the generation of mature ribosomal RNAs from a nascent
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polycistronic transcript. Different steps in pre-rRNA processing may be affected depending
on whether the ribosomal protein is a component of the large or small subunit, the nature in
which it interacts with rRNA and other factors involved in its incorporation into the
assembling subunit [6, 10, 18, 19]. Thus, ribosomal protein deficiencies are associated with
characteristic pre-rRNA processing signatures, which in turn can be used to infer their
functions in ribosome biogenesis. This tool has most often been used retrospectively to
support a gene assignment in DBA but, as we demonstrate, can also be used prospectively to
guide gene discovery.

NIH-PA Author Manuscript

Here, we describe an infant presenting with a severe macrocytic anemia, neutropenia and
congenital anomalies both typical and atypical of DBA. Testing for common inherited bone
marrow failure syndromes failed to identify a cause. Additional study revealed a deletion on
chromosome 2 encompassing RPL31, a gene encoding a protein of the 60S ribosomal
subunit which has not been previously linked to DBA [20]. The effects of decreased
expression of this gene on ribosome synthesis and erythroid differentiation validate RPL31
as a new DBA gene. Importantly, these studies also revealed a novel feature of the 60S
subunit pre-rRNA processing pathway that can be readily evaluated in diagnostic
laboratories and therefore be a useful adjunctive test in establishing a diagnosis in as many
as 20-25% of patients with DBA.

Methods
Array Comparative Genomic Hybridization (aCGH)
aCGH of peripheral blood DNA was performed in a clinical laboratory using a custom
180,000 probe microarray (Agilent Technologies). The putative deletion was confirmed in
the proband, and excluded in the parents, by metaphase FISH analysis of peripheral blood
using probe RP11-352P9. Deletion and phenotype data regarding the index RPL31 DBA
case were submitted to the DBA Mutation Database at http://www.dbagenes.unito.it [21,
22].
Pre-rRNA Processing Studies
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This DBA study is registered at ClinicalTrials.gov (NCT00106015). Non-DBA patient RNA
was obtained from pediatric hematology/oncology (age 2-17 years) patients without a
suspected diagnosis of bone marrow failure (Hemoglobin SS, SC, or S-β thalassemia,
acquired immune thrombocytopenia, iron deficiency anemia or history of oncologic disorder
more than 1 year off therapy). Informed consent was obtained from patients or guardian and
family members under participating institutional protocols according to the Declaration of
Helsinki. Concanavalin A-stimulated (ConA) peripheral blood mononuclear cells (PBMC)
were prepared as described previously [7]. Total RNA was isolated using RNeasy kits
(Qiagen). RNA was fractionated on a 1.5% formaldehyde-agarose gel and ethidium bromide
stained gels were visualized. For Northern analysis, gel-fractionated RNA was transferred to
zeta-probe membranes (Bio-Rad). Oligonucleotide probes complementary to ITS1 and ITS2
were labeled with 32P using T4 polynucleotide kinase. Probes were hybridized overnight
with membranes at 37° C in ULTRAHyb-Oligonucleotide hybridization buffer (Ambion).
Membranes were washed at 37° C with 6XSSC and subjected to phosphorimaging analysis.
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For the Bioanalyzer studies, RNA was run on the Bioanalyzer 2100 (Agilent Technologies)
capillary electrophoresis system using the RNA Nano chip (Agilent Technologies)
according to the manufacturer’s protocol. Peak integration was performed using 2100 Expert
(Agilent Technologies) software in fragment analysis mode using software-defined 18S and
28S peaks; the 32S peak was manually selected as the minor peak just larger than 28S
rRNA. Interpretation was performed blinded to the identities of the individuals studied.
Between-group 32S pre-rRNA data were analyzed using a two-tailed Mann Whitney test.
Lentiviral Vector Construction
Oligonucleotides encoding RPL31 shRNA [TRC Clone ID TRCN0000291963 [23]] and
luciferase shRNA were phosphorylated by T4 polynucleotide kinase, annealed and ligated
into pLKO.1 vector digested with EcoRI and AgeI [24].
Lentiviral Vector Production
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293T cells (2 × 106) were plated in a 6-cm dish in DMEM supplemented with 10% FCS
(Hyclone), with 4 mM glutamine, 50 mg/mL penicillin, and 50 U/mL streptomycin. The
cells were transfected with 3 plasmids (3 μg packaging construct, 1 μg envelope construct,
and 4 μg pLKO with shRNA insert) using lipofectamine and OPTI-MEM (Invitrogen). After
6 hrs the transfection medium was changed. Virus containing supernatant was collected after
48 hrs, pooled, filtered through a 0.45μm filter and stored at −80° C. The titer of lentivirus
was evaluated by slot blot analysis of RNA extracted from virus containing medium
compared to known numbers of infectious particles.
Transduction of Cells
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K562 cells were cultured in 12 well plates (2 × 105 cells/well) DMEM (Invitrogen) + 10%
FBS (HyClone). For transduction, one half volume of medium was replaced with viruscontaining medium with polybrene added to a final concentration of 2 μg/ml. After 24 hours,
fresh media was added containing 1.5 μg/mL of puromycin. The media was replaced after
48 hours in selection and cells were harvested for RNA analysis at 96 hours after
transduction. CD34+ human peripheral blood stem and progenitor cells were a kind gift from
Harry Malech (NIAID). CD34+ cells were cultured in 12 well plates (1.5 × 105 cells/well)
for 12 hrs (hour 0-12 after plating) in proliferation media consisting of StemSpan SerumFree Expansion Medium (Stemcell Technologies) supplemented with 100 U/mL penicillin/
streptomycin (Invitrogen), 2 mM glutamine (Invitrogen), 40 μg/mL human LDL (Stemcell
Technologies), 100 ng/mL stem cell factor, 50 ng/mL thrombopoietin, 10 ng/mL IL-3, 10
ng/mL IL-6 (all Peprotech) and 0.5 U/mL erythropoietin (Stemcell Technologies). For
transduction, one half volume of medium was replaced by virus-containing medium and
polybrene was added to a final concentration of 2 μg/ml. After 24 hours (hour 36 following
plating), fresh proliferation media was added containing 1.5 μg/mL of puromycin. After 48
hours in selection (84+ hours after plating), cells were cultured for 7 days in differentiation
media consisting of proliferation media supplemented to a final concentration of 3 U/mL
erythropoietin.
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Cells were analyzed by FACS Calibur 1 flow cytometer (BD Biosciences) after staining
with FITC-conjugated anti-CD235 and PE-conjugated anti-CD41 antibodies (BD
Biosciences). Data were analyzed in FlowJo Version 8.8.6 (TreeStar).
Quantitative RT-PCR (qRT-PCR)
Total RNA was reverse transcribed using Quantitect RT kit (Qiagen). The level of RPL31
mRNA was analyzed by qRT-PCR on a 7500 Real-time system (Applied Biosystems) using
Power Syber green mix (Applied Biosystems) for detection of PCR products. cDNA (1 μL)
was used in a 25-μL final volume reaction with 400 nM primers. RPL31 was internally
normalized against GAPDH and compared in reference to cells transduced with luciferase
shRNA.
RPL31 Mutation and Deletion Analysis
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RPL31 target regions were amplified and directly sequenced by PCR from peripheral blood
DNA with primers as shown in supplementary table 1 on a 3730xl DNA analyzer (Applied
Biosystems). Detected variants were submitted to NCBI dbSNP under batch ID RPL31R109_ISDP1-20100921. SNP array for copy number analysis of peripheral blood DNA was
performed as previously reported [7] and appended to the NCBI/Gene Expression Omnibus
series record, GSE31575. Confidence intervals were calculated by the modified Wald
method.

Results
Identification of Copy Loss Involving RPL31
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A female infant of Hispanic and Caucasian ancestry presented at four months of age with
severe, macrocytic anemia (Hemoglobin 2 g/dL, MCV 130 fL) and neutropenia (absolute
neutrophil counts [ANC] averaging 300/μL) with variably elevated platelet counts (range 3
× 105 – 8 × 105/μL). Bone marrow evaluation revealed decreased cellularity for age
(50-60%) with an absence of erythroid precursors, myeloid hypoplasia with maturation
arrest, increased numbers of megakaryocytes, lymphocytosis and eosinophilia (Figs. 1A and
1B). The bone marrow karyotype was normal. She had multiple congenital anomalies
including bilateral proximal radioulnar synostosis (RUS, Fig. 1C), a left triphalangeal thumb
(Fig. 1D) and right thenar hypoplasia. She had normal cardiac anatomy by
echocardiography, but abdominal ultrasound at 4 months demonstrated a small spleen
(reference mean length and standard deviation for age is 5.2/0.47 cm), measuring 2.5 cm
[25].
Chromosome breakage assay for Fanconi anemia (FA) was within normal limits and
sequence analysis revealed no mutations in the Shwachman Diamond syndrome (SDS) gene
(SBDS). Nine ribosomal protein genes known to be involved in DBA and available for
clinical testing were sequenced, revealing only 2 synonymous single nucleotide
polymorphisms, one each in RPS19 and RPL11. Red blood cell transfusions precluded an
accurate determination of erythrocyte adenosine deaminase activity, which is elevated in
85% of patients with DBA [26].
Am J Hematol. Author manuscript; available in PMC 2015 February 18.
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The patient remained red cell transfusion-dependent throughout her first year of life, with
hemoglobin concentrations typically falling to < 6 g/dL within three weeks following
transfusion. Although neutropenic at baseline and requiring hospital admission and empiric
antibiotic therapy on several occasions for fever with neutropenia, she did not develop
clinically significant bacterial infections during this time. She subsequently achieved
acceptable peripheral neutrophil counts (average ANC 3,000/μL) with granulocyte colonystimulating factor administered at 5 mcg/kg thrice weekly beginning at 7 months of age. She
was vaccinated in the first year of life according to Advisory Committee on Immunization
Practices guidelines, including 3 doses of conjugated Pneumococcal (PCV13) vaccine. At 12
months of age she presented with, and subsequently died as a result of, overwhelming S.
pneumoniae sepsis. The family declined post-mortem examination.
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Comparative genomic hybridization (CGH) and subsequent confirmatory fluorescence in
situ hybridization (FISH) revealed a 3.2 Mb deletion on chromosome 2 (2q11.2,
chr2:99,028,236 – 102,253,369, GRCh37/hg19) that was not found in either parent. The
deletion at 2q11.2 involves 30 genes annotated in the NCBI RefSeq database (Fig. 1E) and
includes RPL31, a 60S ribosomal subunit gene, suggesting haploinsufficiency for RPL31 as
a potential explanation for her syndrome. However, as RPL31 has not been previously
identified as a DBA gene, we addressed whether the 2q11.2 deletion was associated with a
defect in ribosome biogenesis in the proband.
Pre-rRNA Processing Defects in RPL31-Deficient Primary Cells
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To determine whether the 2q11.2 deletion is associated with defective ribosome biogenesis,
we analyzed pre-rRNA processing in ConA-stimulated PBMC by Northern blot analysis of
total RNA derived from the proband, her parents, and a healthy control. Because RPL31
encodes a protein of the 60S ribosomal subunit, we initially assessed pre-rRNA processing
using an oligonucleotide probe complementary to sequences within an internal spacer, ITS2
(Supplementary Fig. S1). We identified a prominent increase in 32S pre-rRNA in the
proband compared to parents and control (Fig. 2A). The 32S pre-rRNA contains the mature
5.8S and 28S RNAs of the 60S ribosomal subunit separated by ITS2. Cleavage within ITS2
ultimately gives rise to the 3′ end of 5.8S RNA and the 5′ end of 28S RNA (Supplementary
Fig. S1). Thus, a pre-rRNA processing defect affecting the 32S pre-rRNA and the
subsequent production of mature 28S RNAs is consistent with haploinsufficiency of RPL31,
a large subunit ribosomal protein gene.
We also investigated the pre-rRNA processing steps associated with maturation of the 40S
subunit using an oligonucleotide complementary to sequences within ITS1, which
hybridizes to rRNA precursors of the small ribosomal subunit (Supplementary Fig. S1).
These studies demonstrated modestly decreased 30S pre-rRNA in the proband relative to
controls. Unexpectedly, the proband also had increased levels of 18SE pre-rRNA, the
immediate precursor to mature 18S rRNA (Fig. 2B). This late step in pre-rRNA maturation
occurs after 40S subunit precursors are transported from the nucleus to the cytoplasm [27].
Since is it unusual for the reduced expression of a large subunit ribosomal protein to affect
such a specific step in the maturation of small ribosomal subunits, we considered the
possibility that the proband may have more than a single defect in ribosome synthesis,
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potentially resulting from an unidentified mutation in another ribosomal protein gene or in
other genes critical for ribosome synthesis.
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Depletion of RPL31 Mimics the Pre-rRNA Processing Abnormality of Patient Cells
To determine whether the effects observed on pre-rRNA processing in the proband could be
exclusively attributed to haploinsufficiency for RPL31, we examined pre-rRNA processing
in human K562 cells depleted of RPL31 mRNA by RNA interference. These studies
revealed a virtually identical pre-rRNA processing pattern compared to that of the proband
(Figs. 2C and 2D). Thus, the complex pre-rRNA processing phenotype observed in the
proband can be attributed to haploinsufficiency for RPL31 alone (Fig 2E).
Haploinsufficiency for RPL31 Impairs Erythroid Differentiation
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To assess the effects of reduced amounts of RPL31 on erythropoiesis, we transduced normal
human CD34+ hematopoietic progenitors with lentiviral vectors expressing shRNA against
RPL31 or luciferase mRNA and cultured in conditions promoting erythroid differentiation.
Under these conditions, most differentiating progenitors transduced with control shRNA
undergo erythroid differentiation as measured by CD235 (glycophorin A) expression
(Supplementary Fig. S2A). Erythroid differentiation is markedly inhibited in hematopoietic
progenitors following RPL31 mRNA knockdown (Supplementary Fig. S2B), with a 100fold reduction in the proportion of CD235+ cells and a marked decrease in the erythroid
(CD41−/CD235+) /megakaryocyte (CD41+/CD235-) ratio (Supplementary Fig. S2C). Thus,
reduced levels of RPL31 inhibit erythroid differentiation in a manner consistent with that of
the previously established DBA-associated ribosomal protein genes.
RPL31 Alterations Are Rare in DBA
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Due to phenotypic similarity to the RPL31 index patient, we studied a previously reported
DBA patient who lacked detectable alterations in the known DBA genes. Like the index
case, this patient had proximal RUS (reported in [28]) and later developed intermittent
neutropenia and thrombocytosis. We identified a de novo, intron 1 splice donor site mutation
(c.1-386G>A) in this proband (Supplementary Fig. 3). Although inclusion of intron 1 in
the mature mRNA does not disrupt the coding sequence, it is predicted to generate 2 openreading frames (ORF) upstream of the RPL31 ORF and thus may impair translation of
RPL31 mRNA.
To further assess the frequency of RPL31 mutations, we sequenced the coding region,
intron/exon boundaries and untranslated regions of RPL31 in 75 DBA probands as a part of
the Diamond Blackfan Anemia Registry ribosomal protein gene-resequencing project. We
were unable to identify additional putative disease-causing single nucleotide or small
insertion/deletion variants of RPL31 in this cohort of patients (0/75; 95% CI 0-5.8%). Primer
sequences and all detected sequence variants are shown in the Supplementary Materials
(Supplementary Tables S1 and S2). We were similarly unable to identify deletions
involving RPL31 by SNP microarray genotyping in 75 DBA probands who lack a known
DBA gene mutation.
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Elevated 32S pre-rRNA is a Consistent Feature in DBA Patients with Mutations in the
Commonly Mutated Large Ribosomal Subunit Genes

NIH-PA Author Manuscript

As noted above, 32S pre-rRNA is increased in PBMC from a DBA patient where RPL31
was lost by deletion. Remarkably, increased 32S pre-rRNA is evident in these patientderived cells by ethidium bromide staining of RNA fractionated by agarose electrophoresis
(Fig. 3A). We reasoned that this result could be of diagnostic utility if it were generalizable
to other patients harboring mutations in ribosomal proteins of the 60S subunit.
We examined a total of 6 patients with mutations in RPL5 and 2 patients with mutations in
RPL11 (Supplementary Table S3), the most frequently mutated DBA genes encoding 60S
subunit ribosomal proteins, estimated to cause 7 and 10% of all DBA cases, respectively
[29]. We also analyzed one patient with a mutation in RPL35A, a less commonly mutated
DBA gene. Elevated levels of 32S pre-rRNA are evident by ethidium bromide staining in all
of these patient samples. Figure 3B shows the results from two independent specimens from
patients with mutations in RPL5, both of which show elevated levels of 32S pre-rRNA.
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Representative data for a larger series of patients with DBA, some harboring mutations in
known DBA genes and other cases where the genetic lesions remain to be identified, are
illustrated (Fig. 3C). The patient with a mutation in RPL11 clearly shows elevated levels of
32S pre-rRNA evident by ethidium bromide staining as well as Northern blotting. The same
is true for sample DBA2, from a patient whose gene is presently unknown, but clearly shows
elevated levels of 32S pre-rRNA indicating a defect in the maturation of 60S ribosomal
subunits. The two remaining samples include a patient with a mutation in RPS26 and a
second sample, DBA1, obtained from a patient whose gene is also presently unknown. The
RPS26-mutated sample does not show a detectable increase in 32S pre-rRNA, but rather
shows an accumulation of 18SE-pre-rRNA, as was previously shown for patients with
mutations in RPS26 [4]. DBA1, in contrast, shows no evidence of a processing defect
affecting either ribosomal subunit in these analyses.
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To date we have only identified a single patient with a 60S subunit ribosomal protein gene
alteration (RPL15) that did not exhibit an increase in 32S pre-rRNA (Supplementary Figs.
S4A and S4D-E). This result for RPL15 was confirmed using shRNA to reduce RPL15
expression in K562 cells (Supplementary Figs. S4B-C and S4F). Our results for this
patient are consistent with results recently published data for the index RPL15 DBA patient
where an increase in 32S pre-rRNA was not evident [12].
A Clinically Feasible Screening Assay for 60S Subunit Ribosomal Protein Gene
Abnormalities
While agarose gels and ethidium bromide staining are routinely used in research
laboratories, they are challenging to quantitate and unwieldy for clinical application.
However, rRNAs are routinely quantified as a proxy for total RNA integrity for numerous
downstream applications using capillary electrophoresis technology, suggesting a method by
which these observations could be translated into a clinically tractable diagnostic assay. We
reasoned it should also be possible to quantify the increase in 32S pre-rRNA that was
observed in patients with DBA secondary to large ribosomal gene alterations.
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We evaluated ConA-stimulated PBMC RNA from seven DBA patients with 60S subunit
gene defects, five with 40S subunit defects and 19 non-DBA individuals. A minor peak
corresponding to 32S rRNA was discernible in Bioanalyzer trace data from all but 2 nonDBA specimens, with a prominent 32S peak evident in DBA samples with a 60S subunit
gene alteration (Fig. 4). The ratio of 32/28S rRNA was significantly higher in the 60S gene
DBA group (mean 0.058, 95% confidence interval (CI) 0.047 – 0.069) than the 40S gene
group (mean 0.017, 95% CI 0.004 – 0.027) or the control group (mean 0.009, 95% CI 0.006
– 0.012).

Discussion
Diamond Blackfan anemia is one of a number of inherited bone marrow failure syndromes
(IBMFS), many of which have overlapping clinical features that can pose diagnostic
challenges. In the absence of a known causative gene mutation, DBA is often considered as
a diagnosis of exclusion after ruling out other IBMFS. The studies described here were
initiated during the evaluation of a patient posing a significant diagnostic challenge in terms
of differentiating amongst possible IBMFS.
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The patient was an infant with an early, severe and persistent macrocytic anemia with
skeletal abnormalities consistent with DBA or other IBMFS. She also had several features
less frequently observed in DBA, including significant non-erythroid bone marrow
abnormalities. In the context of bone marrow failure syndromes, radial ray abnormalities are
generally associated with FA or thrombocytopenia absent radii (TAR) syndrome; a potential
diagnosis of Fanconi anemia was excluded based on normal chromosome breakage studies.
The presence of persistent neutropenia was potentially compatible with Shwachman
Diamond syndrome, a diagnosis that was largely excluded based on normal SBDS gene
sequence. Similarly, sequencing of the clinically available known DBA genes failed to
define a genetic lesion. Further genomic analysis revealed a large deletion involving RPL31.
We demonstrate here that RPL31 is required for steps in the maturation of 60S ribosomal
subunits in patient cells and, importantly, that decreased expression of RPL31 in human
CD34+ hematopoietic progenitors interferes with erythroid differentiation. These results
strongly suggest DBA as the underlying diagnosis for this patient and identify RPL31 as a
new DBA gene.
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Several additional clinical findings in this case were initially confounding to establishing the
diagnosis of DBA. The unusual phenotypic features might be attributable in part to the
chromosomal deletion, with haploinsufficiency of multiple genes contributing to a
contiguous gene syndrome. There are examples in the literature of patients with DBA
resulting from genomic deletion who have unusual additional features, such as
neurodevelopmental delays, that may reflect a contiguous gene syndrome [30]. However,
recent findings that have expanded our understanding of ribosomopathy-associated disease,
a clearer recognition of the broad phenotypic variations present even in genetically wellclassified IBMFS, and the similarities between this proband and an additional DBA patient
with an RPL31 splice donor mutation make it tempting to speculate that the majority of the
phenotype is attributable to abnormalities of RPL31.
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Neutropenia, although not a classical feature, is clearly prevalent in a subset of patients with
DBA [31]. Thrombocytosis is frequently observed in the 5q- syndrome, a myelodysplastic
syndrome that results from clonally-acquired loss of the 40S ribosomal subunit protein,
RPS14, in bone marrow progenitors [32, 33]. Although radial defects are most typical of FA
and TAR, radial hypoplasia along with triphalangeal thumbs were key phenotypic features
in both DBA siblings described by Aase and Smith [34]. Radioulnar synostosis has also
been associated with amegakaryocytic thrombocytopenia (RUSAT, OMIM #605032), a
disorder caused by heterozygous frameshifting deletions in the homeodomain of HOXA11
[35]. Intriguingly, defective translation of Hox gene mRNA in mice has also been linked to
abnormal skeletal development associated with haploinsufficiency of the non-DBA
associated ribosomal protein gene, Rpl38 [36]. These observations suggest the possibility of
aberrant Hox gene mRNA translation as a potential mechanism for skeletal manifestations
of DBA. Finally, although the available clinical data are incomplete on this point, the
development of fulminant, fatal pneumococcal sepsis and anatomically apparent
hyposplenia are suggestive of a humoral immunologic abnormality. In this regard, there are
reports of hypogammaglobulinemia or common variable immune deficiency in patients with
DBA [6, 37]. Isolated congenital asplenia (ICA, OMIM #271400), another genetically-based
and distinctive abnormality of the humoral immune compartment, has been linked to the
ribosome through the identification of heterozygous mutations of RPSA in a subset of
affected kindreds [38].
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While initial studies suggested that ribosome synthesis could be a common pathological
target in other IBMFS [39], with the exception of DBA and possibly SDS, effects on
ribosome synthesis appear to be secondary or disease modifiers rather than the primary
pathological target of genetic lesions. The ribosome biogenesis defect in SDS appears late in
the pathway involved in the maturation of 60S ribosomal subunits; specific effects on prerRNA processing similar to those observed in patients with DBA have not been reported in
cells from SDS patients [40]. Thus, the pre-rRNA processing defects observed in cells from
patients with DBA could potentially be specifically exploited for diagnostic purposes. The
results reported here suggest a strategy for employing pre-rRNA processing analysis easily
adaptable to a diagnostic setting. We found in both primary cells and knockdown models
that loss of RPL31 leads to accumulation of 32S, an intermediate in the pre-rRNA
processing pathway of the 5.8S and 28S rRNAs of the 60S subunit, and 18SE pre-rRNA, a
late intermediate of the 18S rRNA of the 40S subunit. The surprising finding of altered
small subunit rRNA processing in DBA patients with large subunit gene abnormalities has
not been previously reported, but is potentially significant as a unifying feature of large and
small subunit gene abnormalities. In yeast, the ultimate cytoplasmic steps in 40S maturation,
corresponding to 18SE cleavage, require interaction with mature 60S subunits[41]. Thus it is
possible that abortive large subunit processing may indirectly lead to aberrant 18SE
processing. Although this finding has not been specifically reported in DBA patients, we
note that knockdown of several DBA-associated LSU protein genes (RPL11, RPL19,
RPL26, and RPL15) appears to lead to elevated levels of 18SE pre-rRNA [9, 12].
We found that significant increases of 32S pre-rRNA is a general feature of nearly all DBA
patients with mutations in genes encoding 60S subunit ribosomal proteins. Notably, we
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show that this increase in 32S pre-rRNA can also be detected in total RNA easily
fractionated and quantified by automated capillary electrophoresis (e.g., Bioanalyzer or
similar instrument), providing a functional readout for defects in the maturation of 60S
ribosomal subunits. In addition to the patient described here with a genomic deletion
involving RPL31, we show elevated levels of 32S pre-rRNA in patient samples with
mutations in RPL5 and RPL11, two of the most frequently mutated genes encoding 60S
subunit ribosomal proteins in DBA [10]. To date, we have only identified a single patient
haploinsufficient for a protein of the 60S ribosomal subunit that did not show an increase in
32S pre-rRNA. Alterations involving this gene, RPL15, have been identified in only two
patients with DBA (Supplementary Fig. S4 and [12]).
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Although the sample size in this study is relatively small and will require additional
prospective study to better assess predictive value, these results suggest that deployment of
this functional screening strategy in diagnostic laboratories would allow rapid identification
of pre-rRNA processing defects in approximately 20-25% DBA patients based on current
estimates of the frequency of mutations in genes encoding proteins of the large ribosomal
subunit. Initial functional screening using such a strategy could reduce time to diagnosis and
cut diagnostic costs, by limiting the number of potential genes to be sequenced to attain a
genetic diagnosis. In addition, this assay would allow functional characterization for those
patients with amino acid or weak splicing consensus variants where, in contrast to nonsense
and frameshift mutations, a pathogenic effect is uncertain. Alternative strategies for
employing the Bioanalyzer more broadly in DBA diagnosis, including its use in patients
with mutations in 40S ribosomal protein genes, such as the frequently mutated RPS19 gene,
are also currently under investigation.
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These studies also demonstrate that pre-rRNA processing studies can be used to guide gene
discovery as genome-wide approaches are adopted more broadly to identify novel genes in
DBA. We present data on one patient whose affected gene is currently unknown that clearly
demonstrates a defect in the maturation of 60S rRNA. We would predict that candidate
genes identified should be consistent with this functional study. In addition, we have
identified a patient with no discernible pre-rRNA processing defect. This patient likely joins
an emerging group of DBA patients with mutations in genes that code for proteins with
functions that do not directly impact on the biogenesis of either the 40S or 60S ribosomal
subunit.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Photomicrographs of bone marrow aspiration films from the proband obtained at 6 months
of age demonstrate marrow that is hypocellular for age (50-60% cellularity) with increased
numbers of morphologically normal megakaryocytes, erythroid aplasia, myeloid hypoplasia
with maturation arrest, eosinophilia and lymphocytosis (A, original magnification 200X and
B, original magnification 600X). Plain film radiographs demonstrate proximal radioulnar
synostosis (C) and right triphalangeal thumb (D). The 2q11.2 deletion identified in the
proband is illustrated (E). The involved region, extending from 99,028,236 – 102,253,369
(hg19), is displayed relative to chromosome 2 and enlarged above, with annotated RefSeq
genes indicated by white boxes and labeled by gene symbol. A large ribosomal subunit
gene, RPL31 (black box, middle right), is included in the deleted region.
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Figure 2.
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Northern blot analysis of pre-rRNA processing was performed on primary peripheral blood
mononuclear cells from the proband, her parents, and a normal unaffected individual after
culture for 96 hours in ConA (A and B) and on K562 erythroleukemia cells (C and D) after
transduction with lentivirus expressing shRNA to RPL31 or luciferase (E). Membranes were
interrogated with probes against ITS2 (A and C) and ITS1 (B and D), shown as * above
schematic views of the pre-rRNA species to the right. In comparison to parents and a normal
control, proband lymphocytes demonstrated a marked increase in 32S pre-rRNA abundance
(A), indicative of a large subunit processing defect, as well as increased 45S and 18SE prerRNA, and diminished 30S pre-rRNA, suggesting involvement of small subunit processing
(B). A similar pattern of abnormalities results from RPL31 knockdown in K562 cells (C and
D), indicating that RPL31 haploinsufficiency alone is sufficient to produce these pre-rRNA
processing abnormalities. Error bars indicate the SEM.
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Figure 3.
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Elevated levels of 32S pre-rRNA, which are clearly evident by Northern analysis using a
probe to ITS2 in RPL31-deleted proband RNA (A, upper panel), are also evident on
visualization of the ethidium bromide-stained RNA gel (A, lower panel) from peripheral
blood mononuclear cells after culture for 96 hours in ConA. Similar results were observed in
DBA specimens harboring other large subunit alterations (B, demonstrating two independent
RPL5 mutations) but not normal control RNA. Ethidium bromide-stained and Northern blot
analysis of a larger sample of representative DBA patient RNA demonstrates a prominent
32S band in a patient with a known RPL11 mutation as well as a patient (DBA2) with an
unknown gene mutation. 32S pre-rRNA is not elevated in control RNA or in a patient with
mutation of the small ribosomal subunit gene RPS26. Another patient with unknown
causative mutation (DBA1) lacks clear evidence for either large or small subunit processing
defect. RNA was extracted from peripheral blood mononuclear cells after culture for 96
hours in ConA. Control lanes consist of RNA obtained from unaffected parents of the DBA
proband (Panel A & B) or non-DBA healthy donors (Panel C).
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Figure 4.
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Representative Agilent Bioanalyzer 2100 electrophoretogram data demonstrates prominent
peaks corresponding to 18S and 28S rRNA, with a minor peak just larger than 28S rRNA
corresponding to 32S pre-RNA, that was evident in analysis of total RNA from ConAstimulated peripheral blood mononuclear cells (A). In comparison to non-DBA specimens
(not shown) and DBA specimens with 40S gene alterations (A, upper panel), the 32S peak in
DBA patients with 60S gene abnormalities is prominent (A, lower panel). The 32S/28S ratio
in 7 tested DBA samples with 60S abnormalities is significantly higher than in 19 normal
and 5 DBA specimens from patients with 40S subunit abnormalities (B). The two-tailed Pvalue of Mann Whitney, *** = 0.0001, ** = 0.0025, ns = 0.076.
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